Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Riociguat

FDA-approved product (tablet, oral), marketed as Adempas, Riociguat.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Riociguat
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Hypertension
  • Idiopathic and/or familial pulmonary arterial hypertension
  • Pulmonary arterial hypertension
  • Pulmonary hypertension

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antihypertensives for pulmonary arterial hypertension
FDA pharmacologic class
Soluble Guanylate Cyclase Stimulator FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA46.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli32.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae28.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis68.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Riociguat in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Riociguat with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Discontinuation Versus Continuation of Riociguat Monotherapy in Chronic Thromboembolic Pulmonary Hypertension Successfully Treated With Balloon Pulmonary Angioplasty

    NCT07644377 · start 2026-11-01

    Registered record
    Registry ID
    NCT07644377
    Conditions
    CTEPH
    Interventions
    Discontinuation of riociguat
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-11-01
    Completion
    2031-01-31
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCTEPH
    InterventionDiscontinuation of riociguat
    PhasePhase 3
    Registry statusNot yet recruiting

  • Riociguat in Triple Therapy for Pulmonary Arterial Hypertension in Real-World Practice

    NCT07374302 · start 2026-03-01

    Registered record
    Registry ID
    NCT07374302
    Conditions
    Pulmonary Arterial Hypertension
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-03-01
    Completion
    2026-12-31
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Arterial Hypertension
    InterventionNot recorded
    PhaseNot recorded
    Registry statusNot yet recruiting

  • A Study of Sotatercept for Patients With Eisenmenger Syndrome or Unrepaired Shunt-Associated Pulmonary Arterial Hypertension Resistant to Vasodilator Therapy

    NCT07356778 · start 2025-10-07

    Registered record
    Registry ID
    NCT07356778
    Conditions
    Eisenmenger Syndrome; Pulmonary Arterial Hypertension of Congenital Heart Disease
    Interventions
    Sotatercept; vasodilator-based PAH therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-10-07
    Completion
    2028-04-30
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEisenmenger Syndrome; Pulmonary Arterial Hypertension of Congenital Heart Disease
    InterventionSotatercept; vasodilator-based PAH therapy
    PhasePhase 4
    Registry statusRecruiting

  • Riociguat-Discontinue Effects on Right HEART in CTEPH (RED-HEART)

    NCT06922240 · start 2025-03-21

    Registered record
    Registry ID
    NCT06922240
    Conditions
    Chronic Thromboembolic Pulmonary Hypertension
    Interventions
    Riociguat; Routine Treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-03-21
    Completion
    2027-10-31
    Enrolment
    68

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Thromboembolic Pulmonary Hypertension
    InterventionRiociguat; Routine Treatment
    PhasePhase 3
    Registry statusRecruiting

  • Effects of Combination Medical Therapy Followed by BPA on Right Ventricular-PA Coupling and Hemodynamics in CTEPH

    NCT05140525 · start 2025-01-27

    Registered record
    Registry ID
    NCT05140525
    Conditions
    CTEPH
    Interventions
    Macitentan Tablets; Riociguat; balloon pulmonary angioplasty
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2025-01-27
    Completion
    2026-05-01
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCTEPH
    InterventionMacitentan Tablets; Riociguat; balloon pulmonary angioplasty
    PhasePhase 3
    Registry statusTerminated

  • Efficacy and Safety of Triple-targeted Drug Therapy in Treatment-naive Patients With Non-low-risk PAH: A Real-world, Multicenter Study

    NCT06753981 · start 2024-12-10

    Registered record
    Registry ID
    NCT06753981
    Conditions
    Arterial Pulmonary Hypertension (PAH)
    Interventions
    Endothelin receptor antagonist (ERA) combined with PDE5i/sGC agonist dual therapy prostacyclin drugs
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2024-12-10
    Completion
    2027-02-14
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionArterial Pulmonary Hypertension (PAH)
    InterventionEndothelin receptor antagonist (ERA) combined with PDE5i/sGC agonist dual therapy prostacyclin drugs
    PhaseNot recorded
    Registry statusRecruiting

  • Switching of Sildenafil to Riociguat in CTEPH Patients

    NCT06715280 · start 2024-07-25

    Registered record
    Registry ID
    NCT06715280
    Conditions
    Chronic Thromboembolic Pulmonary Hypertension
    Interventions
    Riociguat (Adempas)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-07-25
    Completion
    2027-01-22
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Thromboembolic Pulmonary Hypertension
    InterventionRiociguat (Adempas)
    PhasePhase 4
    Registry statusRecruiting

  • Effect of Riocigaut on Migraine Attack Induction in People With Migraine

    NCT05750446 · start 2023-06-01

    Registered record
    Registry ID
    NCT05750446
    Conditions
    Migraine Without Aura
    Interventions
    Riociguat (BAY 63-2521); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2023-06-01
    Completion
    2024-02-01
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine Without Aura
    InterventionRiociguat (BAY 63-2521); Placebo
    PhaseNot applicable
    Registry statusCompleted

  • Bioequivalence Study of Riociguat 2.5 mg Film Coated Tablets and Adempas (Riociguat) 2.5 mg Film Coated Tablets

    NCT06180096 · start 2023-03-07

    Registered record
    Registry ID
    NCT06180096
    Conditions
    Pulmonary Arterial Hypertension
    Interventions
    Riociguat film coated tablets; Adempas Filmtabletten
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2023-03-07
    Completion
    2023-04-06
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Arterial Hypertension
    InterventionRiociguat film coated tablets; Adempas Filmtabletten
    PhasePhase 1
    Registry statusCompleted

  • Effect of Riocigaut on Cerebral Vasodilation and Headache Induction in Healthy Volunteers

    NCT05582811 · start 2022-10-26

    Registered record
    Registry ID
    NCT05582811
    Conditions
    Headache
    Interventions
    Dose Riociguat 2,5 or 5mg; Riociguat; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2022-10-26
    Completion
    2023-06-01
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeadache
    InterventionDose Riociguat 2,5 or 5mg; Riociguat; Placebo
    PhaseNot applicable
    Registry statusCompleted

  • Networked Drug REpurposing for Mechanism-based neuroPrOtection in Acute Ischaemic STROKE

    NCT05762146 · start 2022-09-05

    Registered record
    Registry ID
    NCT05762146
    Conditions
    Ischemic Stroke, Acute
    Interventions
    Riociguat; Propylthiouracil; Perphenazine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2022-09-05
    Completion
    2024-04-30
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIschemic Stroke, Acute
    InterventionRiociguat; Propylthiouracil; Perphenazine
    PhasePhase 2
    Registry statusUnknown

  • A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patients in the United States Who Are Receiving Riociguat for High Blood Pressure in the Arteries That Carry Blood From the Heart to the Lungs (Pulmonary Arterial Hypertension, PAH)

    NCT04813926 · start 2021-07-16

    Registered record
    Registry ID
    NCT04813926
    Conditions
    Pulmonary Arterial Hypertension
    Interventions
    Riociguat (Adempas, BAY63-2521)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-07-16
    Completion
    2025-02-03
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Arterial Hypertension
    InterventionRiociguat (Adempas, BAY63-2521)
    PhaseNot recorded
    Registry statusCompleted

  • Initial Dual Oral Combination Therapy Versus Standard-of-care Initial Oral Monotherapy Prior to Balloon Pulmonary Angioplasty in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension

    NCT04780932 · start 2021-06-14

    Registered record
    Registry ID
    NCT04780932
    Conditions
    Thromboembolic Pulmonary Hypertension; Chronic Disease; Inoperable Disease
    Interventions
    Macitentan 10mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2021-06-14
    Completion
    2025-07-03
    Enrolment
    96

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThromboembolic Pulmonary Hypertension; Chronic Disease; Inoperable Disease
    InterventionMacitentan 10mg; Placebo
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Possible Effects of Propylthiouracil, Riociguat and Perphenazine on Circulation of Healthy Volunteers

    NCT04776499 · start 2021-03-18

    Registered record
    Registry ID
    NCT04776499
    Conditions
    Drug Drug Interaction; Safety Issues
    Interventions
    Propylthiouracil, Riociguat, Perphenazine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-03-18
    Completion
    2022-02-28
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Drug Interaction; Safety Issues
    InterventionPropylthiouracil, Riociguat, Perphenazine
    PhasePhase 1
    Registry statusCompleted

  • THERAPY-HYBRID-BPA Trial

    NCT04600492 · start 2020-10-16

    Registered record
    Registry ID
    NCT04600492
    Conditions
    Hypertension, Pulmonary
    Interventions
    Riociguat Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2020-10-16
    Completion
    2025-01-28
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension, Pulmonary
    InterventionRiociguat Oral Tablet
    PhasePhase 2
    Registry statusUnknown